Edition:
India

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

151.65EUR
20 Aug 2019
Change (% chg)

-- (--)
Prev Close
€151.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
397,907
52-wk High
€171.20
52-wk Low
€74.48

Select another date:

Tue, Jul 16 2019

Photo

Gilead invests $5 billion to deepen ties with biotech Galapagos

U.S. antiviral drugmaker Gilead Sciences will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV , news that lifted Galapagos's shares more than 18% to an all-time high on Monday.

Gilead invests $5 billion to deepen ties with biotech Galapagos

U.S. antiviral drugmaker Gilead Sciences will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV , news that lifted Galapagos's shares more than 18% to an all-time high on Monday.

UPDATE 4-Gilead invests $5 bln to deepen ties with biotech Galapagos

* Gilead makes $3.95 bln upfront payment, $1.1 equity investment

Factbox: The Galapagos drugs pipeline that has drawn in Gilead

U.S. antiviral drugmaker Gilead Sciences will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV .

Factbox: The Galapagos drugs pipeline that has drawn in Gilead

U.S. antiviral drugmaker Gilead Sciences will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV.

Pharma firm Gilead to raise Galapagos stake in $5.1 bln deal -report

July 14 Gilead Sciences Inc will increase its stake in Galapagos NV and gain rights outside Europe to the Belgian-Dutch biotech firm's treatments in development in a $5.1 billion deal, the Wall Street Journal reported on Sunday.

BRIEF-Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study

* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Shares in Galapagos jump 15 percent after arthritis drug results

AMSTERDAM Shares in Belgian drugmaker Galapagos surged nearly 16 percent on Friday after the company said it had seen positive results from several safety and efficacy trials of its rheumatoid arthritis drug filgotinib.

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES

BRIEF-Galapagos FY Revenue Up At 317.8 Million Euros

* SAID ON THURSDAY FY REVENUE EUR 317.8 MLN VS EUR 155.9 MLN YR AGO

Select another date: